62 related articles for article (PubMed ID: 38527014)
21. Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer.
Ray-Coquard I; Pautier P; Pignata S; Pérol D; González-Martín A; Berger R; Fujiwara K; Vergote I; Colombo N; Mäenpää J; Selle F; Sehouli J; Lorusso D; Guerra Alía EM; Reinthaller A; Nagao S; Lefeuvre-Plesse C; Canzler U; Scambia G; Lortholary A; Marmé F; Combe P; de Gregorio N; Rodrigues M; Buderath P; Dubot C; Burges A; You B; Pujade-Lauraine E; Harter P;
N Engl J Med; 2019 Dec; 381(25):2416-2428. PubMed ID: 31851799
[TBL] [Abstract][Full Text] [Related]
22. Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer.
Moore K; Colombo N; Scambia G; Kim BG; Oaknin A; Friedlander M; Lisyanskaya A; Floquet A; Leary A; Sonke GS; Gourley C; Banerjee S; Oza A; González-Martín A; Aghajanian C; Bradley W; Mathews C; Liu J; Lowe ES; Bloomfield R; DiSilvestro P
N Engl J Med; 2018 Dec; 379(26):2495-2505. PubMed ID: 30345884
[TBL] [Abstract][Full Text] [Related]
23. Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation.
Litton JK; Rugo HS; Ettl J; Hurvitz SA; Gonçalves A; Lee KH; Fehrenbacher L; Yerushalmi R; Mina LA; Martin M; Roché H; Im YH; Quek RGW; Markova D; Tudor IC; Hannah AL; Eiermann W; Blum JL
N Engl J Med; 2018 Aug; 379(8):753-763. PubMed ID: 30110579
[TBL] [Abstract][Full Text] [Related]
24. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation.
Robson M; Im SA; Senkus E; Xu B; Domchek SM; Masuda N; Delaloge S; Li W; Tung N; Armstrong A; Wu W; Goessl C; Runswick S; Conte P
N Engl J Med; 2017 Aug; 377(6):523-533. PubMed ID: 28578601
[TBL] [Abstract][Full Text] [Related]
25. Homologous Recombination Deficiency (HRD) Score Predicts Response to Platinum-Containing Neoadjuvant Chemotherapy in Patients with Triple-Negative Breast Cancer.
Telli ML; Timms KM; Reid J; Hennessy B; Mills GB; Jensen KC; Szallasi Z; Barry WT; Winer EP; Tung NM; Isakoff SJ; Ryan PD; Greene-Colozzi A; Gutin A; Sangale Z; Iliev D; Neff C; Abkevich V; Jones JT; Lanchbury JS; Hartman AR; Garber JE; Ford JM; Silver DP; Richardson AL
Clin Cancer Res; 2016 Aug; 22(15):3764-73. PubMed ID: 26957554
[TBL] [Abstract][Full Text] [Related]
26. Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers.
Watkins JA; Irshad S; Grigoriadis A; Tutt AN
Breast Cancer Res; 2014 Jun; 16(3):211. PubMed ID: 25093514
[TBL] [Abstract][Full Text] [Related]
27. Patterns of genomic loss of heterozygosity predict homologous recombination repair defects in epithelial ovarian cancer.
Abkevich V; Timms KM; Hennessy BT; Potter J; Carey MS; Meyer LA; Smith-McCune K; Broaddus R; Lu KH; Chen J; Tran TV; Williams D; Iliev D; Jammulapati S; FitzGerald LM; Krivak T; DeLoia JA; Gutin A; Mills GB; Lanchbury JS
Br J Cancer; 2012 Nov; 107(10):1776-82. PubMed ID: 23047548
[TBL] [Abstract][Full Text] [Related]
28. Ploidy and large-scale genomic instability consistently identify basal-like breast carcinomas with BRCA1/2 inactivation.
Popova T; Manié E; Rieunier G; Caux-Moncoutier V; Tirapo C; Dubois T; Delattre O; Sigal-Zafrani B; Bollet M; Longy M; Houdayer C; Sastre-Garau X; Vincent-Salomon A; Stoppa-Lyonnet D; Stern MH
Cancer Res; 2012 Nov; 72(21):5454-62. PubMed ID: 22933060
[TBL] [Abstract][Full Text] [Related]
29. Telomeric allelic imbalance indicates defective DNA repair and sensitivity to DNA-damaging agents.
Birkbak NJ; Wang ZC; Kim JY; Eklund AC; Li Q; Tian R; Bowman-Colin C; Li Y; Greene-Colozzi A; Iglehart JD; Tung N; Ryan PD; Garber JE; Silver DP; Szallasi Z; Richardson AL
Cancer Discov; 2012 Apr; 2(4):366-375. PubMed ID: 22576213
[TBL] [Abstract][Full Text] [Related]
30. PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene.
Rahman N; Seal S; Thompson D; Kelly P; Renwick A; Elliott A; Reid S; Spanova K; Barfoot R; Chagtai T; Jayatilake H; McGuffog L; Hanks S; Evans DG; Eccles D; ; Easton DF; Stratton MR
Nat Genet; 2007 Feb; 39(2):165-7. PubMed ID: 17200668
[TBL] [Abstract][Full Text] [Related]
31. In search of the tumour-suppressor functions of BRCA1 and BRCA2.
Scully R; Livingston DM
Nature; 2000 Nov; 408(6811):429-32. PubMed ID: 11100717
[TBL] [Abstract][Full Text] [Related]
32. Embryonic lethality and radiation hypersensitivity mediated by Rad51 in mice lacking Brca2.
Sharan SK; Morimatsu M; Albrecht U; Lim DS; Regel E; Dinh C; Sands A; Eichele G; Hasty P; Bradley A
Nature; 1997 Apr; 386(6627):804-10. PubMed ID: 9126738
[TBL] [Abstract][Full Text] [Related]
33. Prediction of homologous recombination deficiency from Oncomine Comprehensive Assay Plus correlating with SOPHiA DDM HRD Solution.
Kang J; Na K; Kang H; Cho U; Kwon SY; Hwang S; Lee A
PLoS One; 2024; 19(3):e0298128. PubMed ID: 38527014
[TBL] [Abstract][Full Text] [Related]
34. Homologous Recombination Deficiency (HRD) in Cutaneous Oncology.
Akinjiyan FA; Morecroft R; Phillipps J; Adeyelu T; Elliott A; Park SJ; Butt OH; Zhou AY; Ansstas G
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37445949
[TBL] [Abstract][Full Text] [Related]
35. New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors.
Liu FW; Tewari KS
Curr Treat Options Oncol; 2016 Mar; 17(3):12. PubMed ID: 26931795
[TBL] [Abstract][Full Text] [Related]
36. Homologous recombination deficiency real-time clinical assays, ready or not?
Fuh K; Mullen M; Blachut B; Stover E; Konstantinopoulos P; Liu J; Matulonis U; Khabele D; Mosammaparast N; Vindigni A
Gynecol Oncol; 2020 Dec; 159(3):877-886. PubMed ID: 32967790
[TBL] [Abstract][Full Text] [Related]
37. Testing for homologous recombination repair or homologous recombination deficiency for poly (ADP-ribose) polymerase inhibitors: A current perspective.
Herzog TJ; Vergote I; Gomella LG; Milenkova T; French T; Tonikian R; Poehlein C; Hussain M
Eur J Cancer; 2023 Jan; 179():136-146. PubMed ID: 36563604
[TBL] [Abstract][Full Text] [Related]
38. Cracking the homologous recombination deficiency code: how to identify responders to PARP inhibitors.
Paulet L; Trecourt A; Leary A; Peron J; Descotes F; Devouassoux-Shisheboran M; Leroy K; You B; Lopez J
Eur J Cancer; 2022 May; 166():87-99. PubMed ID: 35279473
[TBL] [Abstract][Full Text] [Related]
39. The role of homologous recombination deficiency testing in ovarian cancer and its clinical implications: do we need it?
Ngoi NYL; Tan DSP
ESMO Open; 2021 Jun; 6(3):100144. PubMed ID: 34015643
[TBL] [Abstract][Full Text] [Related]
40. Homologous Recombination Deficiency and Ovarian Cancer Treatment Decisions: Practical Implications for Pathologists for Tumor Typing and Reporting.
Rabban JT; Chen LM; Devine WP
Surg Pathol Clin; 2022 Jun; 15(2):219-234. PubMed ID: 35715159
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
